ImmunityBio (IBRX) Other Accumulated Expenses (2014 - 2026)
ImmunityBio (IBRX) reported Other Accumulated Expenses of $2.4 million for Q1 2026, down 7.58% year-over-year from $2.7 million in Q1 2025, and down 20.27% on a QoQ basis from $3.1 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of Other Accumulated Expenses data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Other Accumulated Expenses fell 7.58% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 7.58% YoY) and the FY2025 annual result came in at $3.1 million, up 192.67% from the prior year.
- Other Accumulated Expenses retreated to $2.4 million in Q1 2026 per IBRX's latest filing, from $3.1 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $3.1 million in Q4 2025 and bottomed at $556000.0 in Q1 2024.
- The 5-year median for Other Accumulated Expenses is $1.5 million (2022), against an average of $1.6 million.
- The widest annual swing landed in 2023, when Other Accumulated Expenses slumped 65.82%; it then soared 376.8% in 2025.
- Tracing IBRX's Other Accumulated Expenses over 5 years: stood at $1.6 million in 2022, then plunged by 56.02% to $716000.0 in 2023, then jumped by 46.65% to $1.0 million in 2024, then jumped by 192.67% to $3.1 million in 2025, then decreased by 20.27% to $2.4 million in 2026.
- Per Business Quant, the three latest IBRX Other Accumulated Expenses figures stand at $2.4 million (Q1 2026), $3.1 million (Q4 2025), and $2.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.45 Mn |
| Dec 31, 2025 | 3.07 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 2.65 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 692,000.00 |
| Mar 31, 2024 | 556,000.00 |
| Dec 31, 2023 | 716,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 818,000.00 |
| Mar 31, 2023 | 988,000.00 |
| Dec 31, 2022 | 1.63 Mn |
| Sep 30, 2022 | 1.55 Mn |
| Jun 30, 2022 | 1.65 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 594,000.00 |
| Dec 31, 2020 | 8.82 Mn |
| Sep 30, 2020 | 2.30 Mn |
| Jun 30, 2020 | 75,000.00 |
| Mar 31, 2020 | 3.61 Mn |
| Dec 31, 2019 | 775,000.00 |
| Jun 30, 2019 | 500,000.00 |
| Mar 31, 2019 | 12.50 Mn |
| Dec 31, 2018 | 197,000.00 |
| Sep 30, 2018 | 1.92 Mn |
| Jun 30, 2018 | 1.37 Mn |
| Mar 31, 2018 | 310,000.00 |
| Dec 31, 2017 | 109,000.00 |
| Sep 30, 2017 | 418,000.00 |
| Jun 30, 2017 | 126,000.00 |
| Mar 31, 2017 | 367,000.00 |
| Dec 31, 2016 | 321,000.00 |
| Sep 30, 2016 | 224,000.00 |
| Jun 30, 2016 | 291,000.00 |
| Mar 31, 2016 | 131,000.00 |
| Dec 31, 2015 | 144,000.00 |
| Sep 30, 2015 | 179,000.00 |
| Jun 30, 2015 | 219,000.00 |
| Dec 31, 2014 | 29,000.00 |